ArticlePloS one2021
Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 5 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Evaluating cognitive decline detection in aging populations with single-channel EEG features based on two studies and meta-analysis.Scientific reports · 2025Pooled it
- The EEG analysis and identification of Alzheimer's disease: a review.Frontiers in aging neuroscience · 2025Pooled it
- Effectiveness of Electroencephalography Neurofeedback for Improving Working Memory and Episodic Memory in the Elderly: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2024Pooled it
- The Importance of Subjective Cognitive Decline Recognition and the Potential of Molecular and Neurophysiological Biomarkers-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Brain function effects of exercise interventions for cognitive decline: a systematic review and meta-analysis.Frontiers in neuroscience · 2023Pooled it
- Electroencephalographic Biomarkers of Deep Transcranial Magnetic Stimulation Treatment Response for Major Depressive Disorder in Older Adults: A Preliminary Study.International journal of geriatric psychiatry · 2026Trial
- Randomized, double-blind, sham-controlled pilot trial of theta-band transcranial alternating current stimulation during cognitive training in mild Alzheimer's disease.Translational psychiatry · 2026Trial
- The Acute Effects of Motor Imagery Combined With Action Observation Breathing Exercise on Cardiorespiratory Responses, Brain Activity, and Cognition: A Randomized, Controlled Trial.Cardiovascular therapeutics · 2025Trial
- Effect of combined physical-cognitive training on the functional and cognitive capacity of older people with mild cognitive impairment: a randomized controlled trial.BMC medicine · 2024Trial
- Resting-state functional and spectral alterations underlying cognitive decline in biomarker-confirmed Alzheimer's disease: A systematic review.NeuroImage. Clinical · 2026Article
- Electroencephalography Functional Network Responses to Immersive Virtual Reality in Alzheimer Disease and Mild Cognitive Impairment: Exploratory Single-Session 3-Group Repeated-Measures Study.JMIR serious games · 2026Article
- Leveraging pretrained vision transformers for classifying alcohol use disorder using raw resting-state EEG.Neuroimage. Reports · 2026Article
- Abnormal periodic and aperiodic resting-state electroencephalographic markers in Lewy body and Alzheimer's diseases with cognitive decline.GeroScience · 2026Article
- Quantitative Electroencephalography as a Complement to Symptom-Based Psychiatric Diagnosis: A Narrative Review.Journal of personalized medicine · 2026Review
- Quantitative EEG signatures of power and functional connectivity alterations in Alzheimer's disease and frontotemporal dementia.Scientific reports · 2026Article
- Interpretable Feature-Transformer Framework for Cross-Subject MCI Detection Using Nonlinear Dynamical and Graph-Theoretic EEG Features.Research square · 2026Article
- Wearable EEG devices in the detection of mild cognitive impairment: a systematic review.NPJ digital medicine · 2026Article
- Resting state EEG mediates the association between physical activity and cognitive function in cognitively impaired elderly.Scientific reports · 2026Article
- Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood-Brain Barrier in Targeted Treatment of Alzheimer's Disease.Pharmaceutics · 2026Review
- Divergence of cortical neurophysiology across different neurodegenerative disorders compared to healthy ageing.Progress in neurobiology · 2026Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for the detection and assessment of cognitive decline in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Neurophysiological biomarkers of AD derived from EEG and FDG-PET, once characterized and validated, would expand the set of existing diagnostic molecular biomarkers of AD pathology with associated biomarkers of disease progression and neural dysfunction. Since symptoms of AD often begin to appear later in life, successful identification of EEG-based biomarkers must account for age-related neurophysiological changes that occur even in healthy individuals. To this end, we collected EEG data from individuals with AD (n = 26), MCI (n = 53), and cognitively normal healthy controls stratified by age into three groups: 18-40 (n = 129), 40-60 (n = 62) and 60-90 (= 55) years old. For each participant, we computed power spectral density at each channel and spectral coherence between pairs of channels. Compared to age matched controls, in the AD group, we found increases in both spectral power and coherence at the slower frequencies (Delta, Theta). A smaller but significant increase in power of slow frequencies was observed for the MCI group, localized to temporal areas. These effects on slow frequency spectral power opposed that of normal aging observed by a decrease in the power of slow frequencies in our control groups. The AD group showed a significant decrease in the spectral power and coherence in the Alpha band consistent with the same effect in normal aging. However, the MCI group did not show any significant change in the Alpha band. Overall, Theta to Alpha ratio (TAR) provided the largest and most significant differences between the AD group and controls. However, differences in the MCI group remained small and localized. We proposed a novel method to quantify these small differences between Theta and Alpha bands' power using empirically derived distributions of spectral power across the time domain as opposed to averaging power across time. We defined Power Distribution Distance Measure (PDDM) as a distance measure between probability distribution functions (pdf) of Theta and Alpha power. Compared to average TAR, using PDDF enhanced the statistical significance, the effect size, and the spatial distribution of significant effects in the MCI group. We designed classifiers for differentiating individual MCI and AD participants from age-matched controls. The classification performance measured by the area under ROC curve after cross-validation were AUC = 0.85 and AUC = 0.6, for AD and MCI classifiers, respectively. Posterior probability of AD, TAR, and the proposed PDDM measure were all significantly correlated with MMSE score and neuropsychological tests in the AD group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.